News Releases

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis Using Industry Leading Methods, ONE-seq and  Digenome-seq Showed No Off-Target Editing Across 244

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced new in vivo data from the company’s proprietary lipid nanoparticle (LNP) delivery

New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies Ongoing to Support Planned IND Submission in 2022 Successful $306.7 Million IPO Completed to Enable

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced initial public offering of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 16, 2021-- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its initial public offering of 14,035,789 shares of its common stock

CAMBRIDGE, Mass. — June 1, 2021  — Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Michael F. MacLean, chief financial officer (CFO) of Avidity Biosciences, has joined the company’s

Data Support Continued Development of Single-course Gene Editing Therapies for Treatment of Cardiovascular Disease, Led by VERVE-101 CAMBRIDGE, Mass. — May 19, 2021  — Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene

CAMBRIDGE, Mass. — May 11, 2021  — Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the presentation of additional preclinical data from the company’s gene editing programs for the

CAMBRIDGE, Mass. — May 5, 2021  — Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical,

Results Validate  In Vivo  Liver DNA Base Editing as a Once-and-Done Approach to Treat Coronary Heart Disease by Lowering of LDL Cholesterol and PCSK9 Protein Levels   Company Selects VERVE-101 as Lead Program to Treat Heterozygous Familial Hypercholesterolemia CAMBRIDGE, Mass.